Which medication is considered first-line treatment for mild to moderate inflammatory bowel disease (IBD)?

First-Line Treatment for Mild to Moderate IBD

Mesalamine is the first-line treatment for mild to moderate inflammatory bowel disease, specifically ulcerative colitis. 1, 2

Why Mesalamine is First-Line

• Standard dosing for mild-moderate UC is 2-3 grams/day orally, which can be escalated to 4.8 grams/day for moderate disease or suboptimal response 1, 2
• Mesalamine (5-ASA) remains the established first-line therapy for mild-to-moderate ulcerative colitis based on multiple international guidelines 1, 3, 4
• Doses below 2 grams/day are significantly less effective and should be avoided 2

Disease Location Determines Specific Approach

Extensive or Left-Sided Colitis

• Combination therapy with oral mesalamine (≥2.4 g/day) plus rectal mesalamine (≥1 g/day as enema) is superior to monotherapy 1, 2
• The AGA recommends adding rectal mesalamine to oral therapy for improved remission rates 1

Ulcerative Proctitis

• Mesalamine suppositories 1 gram daily are preferred over oral therapy alone 1, 2
• Topical therapy delivers medication directly to the rectum and is more effective than oral monotherapy for distal disease 2

Proctosigmoiditis

• Use mesalamine enemas (not suppositories) combined with oral mesalamine, as enemas reach the sigmoid colon while suppositories only reach the rectum 2

Why NOT the Other Options

• Ondansetron is an antiemetic with no role in IBD treatment—it addresses nausea but not inflammation 5
• Sulfasalazine can be used but is considered second-line due to higher intolerance rates (up to 15%) compared to mesalamine; it may be reasonable for patients with prominent arthritic symptoms or cost constraints 1, 2
• Famotidine is an H2-blocker for acid suppression with no anti-inflammatory properties relevant to IBD 5

When to Escalate Beyond Mesalamine

• If no response within 10-14 days of rectal bleeding or 40 days without complete remission, add oral prednisone 40 mg/day or budesonide MMX 9 mg/day 2
• Corticosteroids are highly effective for moderate-to-severe disease but are not appropriate for long-term maintenance due to toxicity 1, 6
• Advanced therapies (biologics, JAK inhibitors, S1P agonists) should be initiated if corticosteroids fail within 2 weeks, if taper is unsuccessful, or to avoid repeated corticosteroid courses 1

Critical Practical Points

• Once-daily dosing is as effective as divided doses and improves adherence 2
• Monitor renal function periodically due to rare risk of interstitial nephritis 2
• Do not gradually taper mesalamine when stopping (unlike corticosteroids), but stopping may lead to disease relapse 2
• Underdosing (<2 g/day) is a common pitfall that significantly reduces efficacy 2